title: Recombinant human interleukin-1 alpha: a potent bio-immunomodifier in vivo in immunosuppressed mice induced by cyclophosphamide, retroviral infection and surgical stress.
abstract: Recombinant human Interleukin-1 Alpha (rhu IL-1 alpha) was assessed for its efficacy in modifying the immunosuppression of mice compromised by Cyclophosphamide (CY), retrovirus infection or surgical stress. Sublethal dose (300 mg/kg) of CY caused neutropenia, decreased cellularity of bone marrow and inhibited Natural Killer (NK) cell activity and lymphokine-activated killer (LAK) cell activity in DBA/2 mice. A single dose of rhu IL-1 alpha (1000 units/per mouse) i.p. accelerated recovery of blood neutrophils and bone marrow cellularity and restored NK and LAK cell activity in CY-treated mice. Mice infected with Friend Virus Complex (FVC) had decreased percentages of L3T4+ cells and a reversed L3T4+/Lyt-2+ ratio; NK and LAK cell activity also decreased. These impaired cellular parameters were restored by rhu IL-1 alpha treatment (1000 units/per mouse/daily i.p. starting on day 5 for 5 days). NK and LAK cell activity was impaired by surgical stress. A single dose of rhu IL-1 alpha (1000 units/per mouse) i.p. 20 hours before transfemoral amputation restored NK and LAK cell activity to normal levels in these mice. These studies indicate that rhu IL-1 alpha possesses immunomodulatory effects in vivo for a broad range of stresses.
authors.affiliation: Department of Medicine (Hematology/Oncology), Indiana University, School of Medicine, Indianapolis 46202-5121.
authors.forename: R N
authors.initials: RN
authors.lastname: Shen
authors.forename: B
authors.initials: B
authors.lastname: Wu
authors.forename: L
authors.initials: L
authors.lastname: Lu
authors.forename: H E
authors.initials: HE
authors.lastname: Kaiser
authors.forename: H E
authors.initials: HE
authors.lastname: Broxmeyer
mesh_terms: D000818:Animals; D003520:Cyclophosphamide / Q000494:pharmacology*; D005260:Female; D005622:Friend murine leukemia virus; D006801:Humans; D007165:Immunosuppression Therapy; D007375:Interleukin-1 / Q000494:pharmacology*; D015979:Killer Cells, Lymphokine-Activated / Q000187:drug effects / Q000276:immunology*; D007694:Killer Cells, Natural / Q000187:drug effects / Q000276:immunology*; D007942:Leukemia, Experimental / Q000276:immunology*; D007958:Leukocyte Count / Q000187:drug effects; D008213:Lymphocyte Activation / Q000187:drug effects*; D051379:Mice; D008811:Mice, Inbred DBA; D009503:Neutropenia / Q000139:chemically induced; D011994:Recombinant Proteins / Q000494:pharmacology; D012192:Retroviridae Infections / Q000276:immunology*; D013154:Spleen / Q000187:drug effects / Q000276:immunology; D013312:Stress, Physiological; D014412:Tumor Virus Infections / Q000276:immunology*
chemical_list: D007375:Interleukin-1; D011994:Recombinant Proteins; D003520:Cyclophosphamide